Perrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 3.17%, EPS grew 1,000.0%, free cash flow grew 18.4% and total debt fell 9.78%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PRGO
Perrigo Company plc (PRGO) P/E ratio
Perrigo Company plc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 644× (December 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 47.8× | 16.03% |
| FY2018 | 41.2× | (61.39%) |
| FY2017 | 107× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | n/m |
| PRGO Perrigo Company plc | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. compare | n/m |
| ALVO Alvotech compare | n/m |
| SUPN Supernus Pharmaceuticals, Inc. compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| PBH Prestige Consumer Healthcare Inc. compare | 13.9× |
| ANIP ANI Pharmaceuticals, Inc. compare | 14.9× |
| LQDA Liquidia Corporation compare | 21.9× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)